A composite bifidobacterium agent and its application in yogurt fermentation

By using a combination of complex Bifidobacterium bacteria agent and basic fermentation strains in yogurt, the problem of intolerance to low pH environments of common strains in yogurt is solved, significantly improving the acid resistance and live bacterial number of yogurt, and improving the intestinal tract Healthy and taste, achieving better intestinal peristalsis and texture effects.

CN118652824BActive Publication Date: 2024-11-19JIANGSU WECARE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411148077.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-19
Estimated Expiration
2044-08-21

AI Technical Summary

Technical Problem

The thermophilic subspecies of Salivary Streptococcus salivary and Lactobacillus delhien Bulgarian subspecies are commonly used in existing yogurts to be intolerant of low pH gastric acid environments, resulting in limited number of live bacteria in the intestines, making it difficult to effectively improve the intestinal microecological balance. And adding high doses of probiotics may cause taste and texture problems.

Method used

Using a complex Bifidobacterium fungus agent, combined with the basal fermentation strains of specific types (such as Bifidobacterium animalis subsp. lactis BLa36, Bifidobacterium longum BL21, Bifidobacterium breve BBr60, Bifidobacterium adolescentis BAC30 and Bifidobacterium infantis BI45) Such as Streptococcus thermophilus ST81 and Lactobacillus delhien Bulgarian subspecies LB42, are used for yogurt fermentation, improve the acid resistance and survival rate of yogurt, and improve intestinal health.

Benefits of technology

It significantly increases the acid resistance and number of live bacteria in lactic acid bacteria in yogurt, improves the imbalance of intestinal flora, promotes intestinal peristalsis and gastric motivation, improves the taste and texture of yogurt, and compared with other Bifidobacterium compounding methods, The effect is even better.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118652824B_ABST
    Figure CN118652824B_ABST
Patent Text Reader

Abstract

The present invention relates to a composite bifidobacterium inoculum and its application in yogurt fermentation, wherein the strains in the composite bifidobacterium inoculum are composed of animal bifidobacterium lactis subspecies BLa36 strain, bifidobacterium longum BL21 strain, bifidobacterium breve BBr60 strain, bifidobacterium adolescentis BAC30 strain, and bifidobacterium infantis BI45 strain. The present invention compounds five specific different types of bifidobacterium strains, and there is a potential interaction between the five strains, which can cooperate with each other, synergize in improving the strain gastric juice tolerance and the overall survival rate of the fermented strain, and cooperate with the basic fermented strain for yogurt fermentation, which can significantly improve the acid resistance of lactic acid bacteria in yogurt, and significantly increase the number of live bacteria that enter the human intestinal tract and play a role; and can significantly promote intestinal peristalsis, promote gastric motility, improve the imbalance of intestinal flora, and promote intestinal health.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to a composite bifidobacterium agent and application thereof in yogurt fermentation. Background Art

[0002] The wide variety of microorganisms living in the intestines are important participants in the host's metabolism, and play an important role in the host's food digestion and nutrient absorption, immune regulation, disease defense, etc. When ingested in sufficient amounts, probiotics can have a beneficial effect on the host's health. Probiotics produce beneficial metabolites, while inhibiting the overgrowth of harmful bacteria and promoting the balance of the intestinal environment. Therefore, additional probiotic supplementation is considered an important way to restore intestinal balance. When the balance of the intestinal microecology is disrupted, it may cause symptoms such as irritable bowel syndrome, constipation and diarrhea.

[0003] Yogurt is a good carrier of probiotics. Ordinary yogurt usually contains only basic fermentation bacteria - thermophilic Streptococcus salivarius and Lactobacillus delbrueckii bulgaricus. Although these bacteria play a certain role in the fermentation process, their effect is relatively limited, mainly because thermophilic Streptococcus salivarius and Lactobacillus delbrueckii bulgaricus are difficult to tolerate the low pH gastric acid environment. Therefore, the number of live bacteria of thermophilic Streptococcus salivarius and Lactobacillus delbrueckii bulgaricus that enter the human intestine and play a role is extremely limited. Adding probiotics to yogurt is an important way to increase the number of beneficial live bacteria in the intestine.

[0004] In order to improve the probiotic supplementation effect of yogurt, attempts are being made to develop more types of acid-resistant probiotics, such as bifidobacteria, Lactobacillus acidophilus, Lactobacillus rhamnosus, etc. These probiotics have stronger acid resistance and can better resist the erosion of gastric acid and bile, increasing their survival rate in the intestines. At the same time, the probiotics may bring about taste disturbances and unsatisfactory texture to yogurt. Adding high doses of probiotics to yogurt has always faced major challenges. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a composite bifidobacterium agent and application thereof in yogurt fermentation.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a composite bifidobacterium bacterial agent, wherein the strain in the composite bifidobacterium bacterial agent is composed of animal Bifidobacterium lactis subsp. Bifidobacterium animalis subsp. lactis BLa36 strain, Bifidobacterium longum with a deposit number of CGMCC No. 10452 Bifidobacterium longumBL21 strain, Bifidobacterium breve with a deposit number of CGMCC No. 12915 Bifidobacterium breve BBr60 strain, Bifidobacterium adolescentis with a deposit number of CGMCC No. 19884 Bifidobacterium adolescentis BAC30 strain, Bifidobacterium infantis with a deposit number of CGMCC No. 15134 Bifidobacterium infantis BI45 strain composition.

[0008] The present invention has developed a new probiotic compounding method, which is to compound five specific different types of bifidobacterium strains, and found that there is a potential interaction between the five strains, which can cooperate with each other, and synergize in improving the gastric juice tolerance of the strain and the overall survival rate of the fermented strain. The basic fermentation strain is used for yogurt fermentation, which can significantly improve the acid resistance of lactic acid bacteria in yogurt, and significantly increase the number of live bacteria that enter the human intestine and play a role; and the prepared yogurt has a fine texture, rich taste, and rich aroma; and can significantly promote intestinal peristalsis, promote gastric motility, improve the imbalance of intestinal flora, and promote intestinal health. When using the same amount of bacteria, compared with other bifidobacterium compounding methods, the composite bifidobacterium agent involved in the present invention is more excellent in the performance of the above-mentioned effects.

[0009] Preferably, the ratio of the viable cell counts of the BLa36 strain, BL21 strain, BBr60 strain, BAC30 strain, and BI45 strain is (1-10):(1-10):(1-10):(1-5):(1-5).

[0010] The specific point values ​​in (1-10) can be selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.; the specific point values ​​in (1-5) can be selected from 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, etc.; other specific point values ​​within the above numerical ranges can be selected, and they will not be listed here one by one.

[0011] Based on the potential cooperative relationship between the five types of bifidobacteria, when they meet the above-mentioned specific ratio of live bacteria count, the effects are more prominent in improving gastric juice tolerance and the overall survival rate of strains, improving yogurt texture, taste, aroma, and promoting intestinal peristalsis and gastric motility.

[0012] Preferably, the total number of viable bacteria in the composite bifidobacterium agent is not less than 1×10 11 CFU / mL or 1×10 11 CFU / g, for example 1×10 11 CFU / mL (CFU / g), 5×10 11 CFU / mL (CFU / g), 1×10 12CFU / mL (CFU / g), 5×10 12 CFU / mL (CFU / g), etc.; other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0013] Preferably, the dosage form of the composite bifidobacterium agent includes solution, lyophilized powder, capsule, tablet or granule.

[0014] When the composite bifidobacterium agent is a freeze-dried powder, it is prepared by the following preparation method:

[0015] The relevant strains are inoculated into the culture medium for activation and fermentation to obtain fermentation broth; the fermentation broth is centrifuged, mixed with a lyophilization protective agent and freeze-dried to obtain bacterial powders of each strain; the bacterial powders of each strain are mixed according to the ratio of the number of live bacteria to obtain the product.

[0016] Preferably, the lyoprotectant comprises any one of skim milk, gelatin, dextrin, gum arabic, dextran, sodium alginate, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

[0017] In a second aspect, the present invention provides a composite probiotic agent, the composite probiotic agent comprising the composite bifidobacterium agent described in the first aspect and a basic agent; the strain in the basic agent is Streptococcus thermophilus with a preservation number of CGMCC No. 15752. Streptococcus thermophilus ST81 strain and Lactobacillus delbrueckii subsp. bulgaricus with a deposit number of CGMCC No. 15751 Lactobacillus delbrueckii subsp. bulgaricus LB42 strain composition.

[0018] The present invention also found that the composite bifidobacterium agent involved in the first aspect is used in yogurt fermentation in combination with thermophilic Streptococcus ST81 strain and Lactobacillus delbrueckii subspecies bulgaricus LB42 strain, which can significantly increase the total active number of lactic acid bacteria in yogurt. The prepared yogurt has a fine texture, rich taste, and strong aroma, and can significantly promote intestinal peristalsis, promote gastric motility, improve the imbalance of intestinal flora, and promote intestinal health.

[0019] Preferably, the ratio of the viable count of the ST81 strain to the LB42 strain is 30:(0.001-10), for example 30:0.001, 30:0.01, 30:0.1, 30:0.5, 30:1, 30:2, 30:3, 30:4, 30:5, 30:6, 30:8, 30:10, etc. Other specific point values ​​within this numerical range can be selected, and they will not be described one by one here.

[0020] The total number of viable bacteria in the basic bacterial agent is not less than 1×10 11 CFU / mL or 1×1011 CFU / g, for example 1×10 11 CFU / mL (CFU / g), 5×10 11 CFU / mL (CFU / g), 1×10 12 CFU / mL (CFU / g), etc.; other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0021] The mass ratio of the composite bifidobacterium bacterial agent to the basic bacterial agent is (10-300):(10-40);

[0022] The specific point values ​​in (10-300) can be selected from 10, 20, 30, 50, 70, 80, 100, 150, 200, 250, 300, etc.; the specific point values ​​in (10-40) can be selected from 10, 15, 20, 25, 30, 35, 40, etc.; other specific point values ​​within this numerical range can be selected, and they will not be listed here one by one.

[0023] The dosage form of the composite probiotic includes solution, lyophilized powder, capsule, tablet or granule.

[0024] In a third aspect, the present invention provides use of the composite bifidobacterium agent described in the first aspect or the composite probiotic agent described in the second aspect in yogurt fermentation.

[0025] Preferably, the yogurt fermentation method comprises:

[0026] (1) Mixing raw milk and compound prebiotics, sterilizing and cooling to prepare a fermentation base;

[0027] (2) Inoculating the composite probiotic into the fermentation base for fermentation.

[0028] Preferably, the composite prebiotics include any one of fructooligosaccharides, galacto-oligosaccharides, xylooligosaccharides, isomaltooligosaccharides, soybean oligosaccharides, inulin, polydextrose, α-lactalbumin or lactoferrin, or a combination of at least two thereof.

[0029] Preferably, the composite prebiotics is 0.01-1% of the fermentation base, such as 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc.

[0030] Preferably, the inoculation amount of the composite probiotic is 20-300 g / T, for example, 20 g / T, 50 g / T, 70 g / T, 80 g / T, 100 g / T, 150 g / T, 200 g / T, 250 g / T, 300 g / T, etc.

[0031] Preferably, the fermentation temperature is 40-43°C, for example, 40°C, 41°C, 42°C, 43°C, etc.; the fermentation time is 5-10 h, for example, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, etc.; the fermentation endpoint is that the acidity reaches 70-80°T (for example, 70°T, 72°T, 75°T, 78°T, 80°T, etc.) or pH=4.3-4.5 (for example, pH=4.3, pH=4.4, pH=4.5, etc.).

[0032] Other specific point values ​​within the above numerical range can be selected and will not be described in detail here.

[0033] In a fourth aspect, the present invention provides use of the composite bifidobacterium agent described in the first aspect or the composite probiotic agent described in the second aspect in the preparation of a product that promotes intestinal motility and intestinal health.

[0034] The products include food, health products or medicines.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] The present invention has developed a new probiotic compounding method, which is to compound five specific different types of bifidobacterium strains, and found that there is a potential interaction between the five strains, which can cooperate with each other, and synergize in improving the gastric juice tolerance of the strain and the overall survival rate of the fermented strain. The basic fermentation strain is used for yogurt fermentation, which can significantly improve the acid resistance of lactic acid bacteria in yogurt, and significantly increase the number of live bacteria that enter the human intestine and play a role; and the prepared yogurt has a fine texture, rich taste, and rich aroma; and can significantly promote intestinal peristalsis, promote gastric motility, improve the imbalance of intestinal flora, and promote intestinal health. When using the same amount of bacteria, compared with other bifidobacterium compounding methods, the composite bifidobacterium agent involved in the present invention is more excellent in the performance of the above-mentioned effects.

[0037] The BLa36 strain involved in the present invention is classified as Bifidobacterium animalis subsp. lactis Bifidobacterium animalis subsp. lactis The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is December 2, 2021. The deposit number is CGMCC No. 24029. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0038] The BL21 strain involved in the present invention is classified and named as Bifidobacterium longum Bifidobacterium longumThe depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is January 27, 2015. The deposit number is CGMCC No. 10452. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0039] The BBr60 strain involved in the present invention is classified and named Bifidobacterium breve Bifidobacterium breve The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is August 29, 2016. The deposit number is CGMCC No. 12915. The address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing.

[0040] The BAC30 strain involved in the present invention is classified and named Bifidobacterium adolescentis Bifidobacterium adolescentis The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is May 28, 2020. The deposit number is CGMCC No. 19884. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0041] The BI45 strain involved in the present invention is classified and named as Bifidobacterium infantis Bifidobacterium infantis The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is December 27, 2017. The deposit number is CGMCC No. 15134. The address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0042] The ST81 strain involved in the present invention is classified as Streptococcus thermophilus Streptococcus thermophilus The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is May 11, 2018. The deposit number is CGMCC No. 15752. The address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0043] The LB42 strain involved in the present invention is classified and named as Lactobacillus delbrueckii subsp. bulgaricus Lactobacillus delbrueckii subsp. bulgaricus The depository is the General Microbiology Center of China Microbiological Culture Collection Administration. The deposit date is May 11, 2018. The deposit number is CGMCC No. 15751. The address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 This is a statistical chart of the abundance of Firmicutes in the cecum of each group of mice;

[0045] Figure 2 This is a statistical chart of the abundance of Bacteroidetes in the cecum of each group of mice;

[0046] Figure 3 This is a statistical chart of the ratio of Firmicutes to Bacteroidetes (F / B) in the cecum of each group of mice;

[0047] Figure 4 This is a statistical chart of the abundance of Lachnospira in the cecum of each group of mice;

[0048] Figure 5 This is a statistical chart of the abundance of Alistipes in the cecum of each group of mice;

[0049] Figure 6 This is a statistical chart of the abundance of Acinetobacter in the cecum of each group of mice. DETAILED DESCRIPTION

[0050] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0051] The culture medium formula involved in the following examples is as follows:

[0052] MRS medium (g / L): peptone 10 g / L, beef extract 10 g / L, glucose 20 g / L, sodium acetate 2 g / L, yeast powder 5 g / L, diammonium hydrogen citrate 2 g / L, K2PO4·3H2O 2.6 g / L, MgSO4·7H2O 0.1 g / L, MnSO4 0.05 g / L, Tween 80 1 mL / L, cysteine ​​hydrochloride 0.5 g / L.

[0053] Preparation Example 1

[0054] This preparation example provides ten kinds of bacterial powder products:

[0055] The BLa36 strain, BL21 strain, BBr60 strain, BAC30 strain, BI45 strain, commercial ATCC55814 strain, commercial ATCC15700 strain, commercial ATCC15703 strain, ST81 strain, and LB42 strain were inoculated into MRS liquid culture medium, cultured at 37°C for 24 h for activation, and activated twice to obtain activation solution; the activation solution was inoculated into MRS liquid culture medium at an inoculum of 3% (v / v), cultured at 37°C for 18 h, and bacterial solution was obtained; the bacterial solution was centrifuged at 4°C and 4000 rpm for 5 min, filtered to obtain bacterial cells, mixed with 5 times the mass of protective agent (20% skim milk), and freeze-dried to obtain BLa36 bacterial powder, BL21 bacterial powder, BBr60 bacterial powder, BAC30 bacterial powder, BI45 bacterial powder, ATCC55814 bacterial powder, ATCC15700 bacterial powder, ATCC15703 bacterial powder, ST81 bacterial powder, and LB42 bacterial powder. The viable bacterial counts were 5×10 11 CFU / g, 1×10 12 CFU / g, 1×10 11 CFU / g, 1×10 12 CFU / g, 6×10 11 CFU / g, 1×10 11 CFU / g, 5×10 11 CFU / g, 1×10 12 CFU / g, 1×10 11 CFU / g, 1×10 11 CFU / g, for future use.

[0056] Preparation Example 2

[0057] This preparation example provides the following composite bifidobacterium agent product:

[0058] (1) Five-bacteria compound probiotic agent 1: Evenly mix BLa36 bacterial powder, BL21 bacterial powder, BBr60 bacterial powder, BAC30 bacterial powder and BI45 bacterial powder in a mass ratio of 2:2:2:1:1 to obtain the five-bacteria compound probiotic agent 1.

[0059] (2) Five-bacteria compound probiotic agent 2: Mix BLa36 powder, BL21 powder, BBr60 powder, BAC30 powder and BI45 powder in a mass ratio of 1:1:2:1:1 to obtain the probiotic agent.

[0060] (3) Five-bacteria compound probiotic agent 3: Mix BLa36 bacterial powder, commercially available ATCC55814 bacterial powder, commercially available ATCC15700 bacterial powder, commercially available ATCC15703 bacterial powder, and BI45 bacterial powder in a mass ratio of 2:2:2:1:1 to obtain the probiotic agent.

[0061] (4) Four-bacteria compound probiotic agent 1: Mix BL21 powder, BBr60 powder, BAC30 powder and BI45 powder in a mass ratio of 2:2:1:1 to obtain the product.

[0062] (5) Four-bacteria compound probiotic agent 2: Mix BLa36 powder, BBr60 powder, BAC30 powder and BI45 powder in a mass ratio of 2:2:1:1 to obtain the product.

[0063] (6) Four-bacteria compound probiotic agent 3: Mix BLa36 powder, BL21 powder, BAC30 powder and BI45 powder in a mass ratio of 2:2:1:1 to obtain the product.

[0064] (7) Four-bacteria compound probiotic agent 4: Mix BLa36 bacterial powder, BL21 bacterial powder, BBr60 bacterial powder and BI45 bacterial powder in a mass ratio of 2:2:2:1 to obtain.

[0065] (8) Four-bacteria compound probiotic agent 5: Mix BLa36 bacterial powder, BL21 bacterial powder, BBr60 bacterial powder and BAC30 bacterial powder in a mass ratio of 2:2:2:1 to obtain.

[0066] (9) Three-bacteria compound probiotic agent: Mix BLa36 powder, BL21 powder and BBr60 powder in a mass ratio of 1:1:1.

[0067] Preparation Example 3

[0068] This preparation example provides the following basic fermentation agent products:

[0069] (1) Basic fermentation agent 1: Mix ST81 bacterial powder and LB42 bacterial powder in a mass ratio of 10:1.

[0070] (2) Basic fermentation agent 2: Mix ST81 bacterial powder and LB42 bacterial powder in a mass ratio of 3:1.

[0071] Example 1

[0072] This embodiment provides a yogurt product, and the preparation method thereof is as follows:

[0073] (1) Add white sugar and compound prebiotics (xylooligosaccharides, fructo-oligosaccharides, and isomalto-oligosaccharides in equal weight ratios) to raw milk and fully dissolve them, wherein the raw milk accounts for 94% of the total weight, the white sugar accounts for 5%, and the compound prebiotics accounts for 1%. Then sterilize at 95°C for 15 minutes, and then quickly cool to 40°C in cold water to prepare the fermentation base material for later use.

[0074] (2) The basic fermentation agent 1 prepared in Preparation Example 3 (inoculation amount of 30 g / T) and the five-bacteria composite probiotic agent 1 prepared in Preparation Example 2 (inoculation amount of 100 g / T) were inoculated into the above-mentioned sterilized fermentation base. The fermentation temperature was 43°C. The fermentation was stopped when the acidity reached 75°T or pH = 4.4, and the mixture was refrigerated at 4°C.

[0075] The number of viable bifidobacteria in the yogurt was counted according to the method in QB / T 4575-2013, and the result showed that the total number of bifidobacteria was 8×10 8 CFU / g yogurt.

[0076] Example 2

[0077] This embodiment provides a yogurt product, and the preparation method thereof is as follows:

[0078] (1) Add white sugar and compound prebiotics (xylooligosaccharides, fructo-oligosaccharides, and isomalto-oligosaccharides in equal weight ratios) to raw milk and fully dissolve them, wherein the raw milk accounts for 94% of the total weight, the white sugar accounts for 5%, and the compound prebiotics accounts for 1%. Then sterilize at 95°C for 15 minutes, and then quickly cool to 40°C in cold water to prepare the fermentation base material for later use.

[0079] (2) The basic fermentation agent 2 prepared in Preparation Example 3 (inoculation amount of 30 g / T) and the five-bacteria composite probiotic agent 2 prepared in Preparation Example 2 (inoculation amount of 100 g / T) were inoculated into the above-mentioned sterilized fermentation base. The fermentation temperature was 40°C. The fermentation was stopped when the acidity reached 75°T or pH = 4.4, and the mixture was refrigerated at 4°C.

[0080] The number of viable bifidobacteria in the yogurt was counted according to the method in QB / T 4575-2013, and the result showed that the total number of bifidobacteria was 4×10 8 CFU / g yogurt.

[0081] Comparative Example 1

[0082] This comparative example provides a yogurt product, and the preparation method thereof is different from that of Example 1 only in that an equal amount of the five-bacteria compound probiotic agent 1 prepared in Preparation Example 2 is replaced by an equal amount of the four-bacteria compound probiotic agent 1 prepared in Preparation Example 2. Other conditions remain unchanged.

[0083] Comparative Example 2

[0084] This comparative example provides a yogurt product, and the preparation method thereof is different from that of Example 1 only in that the five-bacteria compound probiotic agent 1 prepared in Preparation Example 2 is replaced by an equal amount of the four-bacteria compound probiotic agent 2 prepared in Preparation Example 2. Other conditions remain unchanged.

[0085] Comparative Example 3

[0086] This comparative example provides a yogurt product, and the preparation method thereof is different from that of Example 1 only in that the five-bacteria compound probiotic agent 1 prepared in Preparation Example 2 is replaced by an equal amount of the four-bacteria compound probiotic agent 3 prepared in Preparation Example 2. Other conditions remain unchanged.

[0087] Comparative Example 4

[0088] This comparative example provides a yogurt product, and the preparation method thereof is different from that of Example 1 only in that the five-bacteria compound probiotic agent 1 prepared in Preparation Example 2 is replaced by an equal amount of the four-bacteria compound probiotic agent 4 prepared in Preparation Example 2. Other conditions remain unchanged.

[0089] Comparative Example 5

[0090] This comparative example provides a yogurt product, and the preparation method thereof is different from that of Example 1 only in that the five-bacteria compound probiotic agent 1 prepared in Preparation Example 2 is replaced by an equal amount of the four-bacteria compound probiotic agent 5 prepared in Preparation Example 2. Other conditions remain unchanged.

[0091] Comparative Example 6

[0092] This comparative example provides a yogurt product, and the preparation method thereof is different from that of Example 1 only in that an equal amount of the five-bacteria compound probiotic agent 1 prepared in Preparation Example 2 is replaced by the five-bacteria compound probiotic agent 3 prepared in Preparation Example 2. Other conditions remain unchanged.

[0093] Comparative Example 7

[0094] This comparative example provides a yogurt product, and the preparation method thereof is different from that of Example 1 only in that an equal amount of the five-bacteria composite probiotic agent 1 prepared in Preparation Example 2 is replaced by the three-bacteria composite probiotic agent prepared in Preparation Example 2. Other conditions remain unchanged.

[0095] Comparative Example 8

[0096] This comparative example provides a yogurt product, the preparation method of which is different from that of Example 1 only in that the five-bacteria composite probiotic agent 1 prepared in Preparation Example 2 is not inoculated in step (2), and other conditions remain unchanged.

[0097] Test Example 1

[0098] Evaluation of in vitro gastric tolerance:

[0099] (1) Solution preparation:

[0100] Prepare electrolyte solution A: weigh 0.064 g potassium chloride, 0.015 g potassium dihydrogen phosphate, 0.263 g sodium bicarbonate, 0.345 g sodium chloride, 0.003 g magnesium chloride hexahydrate, 0.006 g ammonium carbonate, 1.5 g tryptone, and 0.05 g L-cysteine ​​hydrochloride, add 95 mL distilled water to fully dissolve, adjust the pH to 3.0, and make up to 100 mL.

[0101] Prepare electrolyte solution B: weigh 0.022 g of calcium chloride dihydrate, dissolve it in water and make up to 100 mL.

[0102] Dissolving solution: Weigh 8.5 g of sodium chloride and 0.5 g of L-cysteine ​​hydrochloride monohydrate, add 1000 mL of distilled water and fully dissolve.

[0103] The above three solutions were sterilized at 121℃ for 15 min before use.

[0104] Take 8.0 mL of electrolyte solution A and 1.0 mL of electrolyte solution B in a beaker, add pepsin equivalent to 4000 U, adjust the pH value with 1 mol / L hydrochloric acid solution or 1 mol / L sodium hydroxide solution according to the different simulated gastric fluid conditions in Table 1, make the volume to 10 mL, mix well, and filter through a 0.22 μm sterile filter membrane to prepare simulated gastric fluid, which is prepared and used immediately.

[0105] Table 1

[0106]

[0107] (2) Detection of Bifidobacterium:

[0108] 1.0 g of yogurt prepared in Examples 1-2 and Comparative Examples 1-7 was weighed aseptically, placed in a sterile homogenizing bag containing 99 mL of dissolving solution, and thoroughly mixed. The mixture was beaten with a homogenizer at 10 times per second for 2 min until the sample was evenly dispersed to prepare a sample bacterial solution, which was prepared and used immediately. The total bifidobacterium concentration in the sample bacterial solution was determined according to GB 4789.35-2023 and recorded as N1 (in CFU / mL).

[0109] Take 5.0 mL of simulated gastric fluid and 5.0 mL of sample bacterial solution into a 50 mL centrifuge tube, vortex mix, slowly add about 5 mL of mineral oil on the top of the solution with a rubber-tipped pipette to form an oil seal layer on the top of the solution, place the centrifuge tube in a 37 ℃ constant temperature water bath and culture for the specified treatment time, remove the mineral oil with a rubber-tipped pipette, and determine the total concentration of bifidobacteria, which is recorded as N1' (in CFU / mL).

[0110] The above operation was repeated twice, wherein the results of the total bifidobacterium concentration determination before treatment were recorded as N2 and N3, and the results of the total bifidobacterium concentration determination after treatment were recorded as N2' and N3'.

[0111] Gastric juice tolerance was evaluated by strain survival rate, and the calculation formula was:

[0112] Survival rate (%) = (2N1' / N1+2N2' / N2+2N3' / N3) / 3×100%

[0113] The average survival rate of each group is shown in Table 2:

[0114] Table 2

[0115]

[0116] From the data results in Table 2, it can be seen that the yogurt product obtained by fermenting the composite bifidobacterium inoculant with the basic fermentation inoculant has excellent gastric acid tolerance, wherein the survival rate of bifidobacteria can still reach 83.7% at pH = 2. And compared with the data of Comparative Examples 1-7, if the strain compounding method in the composite bifidobacterium inoculant is changed, the survival rate of bifidobacteria in an acidic environment is significantly reduced, indicating that it affects the gastric acid tolerance of yogurt.

[0117] (3) Detection of lactic acid bacteria:

[0118] 1.0 g of yogurt prepared in Examples 1-2 and Comparative Examples 1-8 was weighed aseptically, placed in a sterile homogenizing bag containing 99 mL of dissolving solution, and thoroughly mixed. The mixture was beaten with a homogenizer at 10 times per second for 2 min until the sample was evenly dispersed to prepare a sample bacterial solution, which was prepared and used immediately. The total lactic acid bacteria concentration in the sample bacterial solution was determined according to GB 4789.35-2023 and recorded as N1 (in CFU / mL).

[0119] Take 5.0 mL of simulated gastric fluid and 5.0 mL of sample bacterial solution into a 50 mL centrifuge tube, vortex mix, slowly add about 5 mL of mineral oil on the top of the solution with a rubber-tipped pipette to form an oil seal layer on the top of the solution, place the centrifuge tube in a 37 ℃ constant temperature water bath and culture for the specified treatment time, remove the mineral oil with a rubber-tipped pipette, and determine the total lactic acid bacteria concentration, which is recorded as N1' (in CFU / mL).

[0120] The above operation was repeated twice, wherein the total lactic acid bacteria concentration measurement results before treatment were recorded as N2 and N3, and the total lactic acid bacteria concentration measurement results after treatment were recorded as N2' and N3'.

[0121] Gastric juice tolerance was evaluated by strain survival rate, and the calculation formula was:

[0122] Survival rate (%) = (2N1' / N1+2N2' / N2+2N3' / N3) / 3×100%

[0123] The average survival rate of lactic acid bacteria in each group (the strains in the composite bifidobacterium agent and the basic fermentation agent are all lactic acid bacteria) is shown in Table 3:

[0124] Table 3

[0125]

[0126] As can be seen from the data results in Table 3, the yogurt product obtained by fermenting with the composite bifidobacterium inoculum and the basic fermentation inoculum involved in the present invention has excellent gastric acid tolerance, wherein the survival rate of all lactic acid bacteria can still reach 81.6% at pH = 2, while the survival rate of lactic acid bacteria in the yogurt product obtained by fermenting with only the basic fermentation inoculum is only 8.7% at pH = 2. And compared with the data of Comparative Examples 1-7, if the strain compounding method in the composite bifidobacterium inoculum is changed, the survival rate of lactic acid bacteria in an acidic environment is significantly reduced, indicating that it affects the gastric acid tolerance of yogurt.

[0127] Test Example 2

[0128] Evaluation of the effect on intestinal motility in mice:

[0129] (1) Experimental animals:

[0130] A total of 120 8-week-old BALB / c male mice (20±2 g) were raised in a clean and quiet environment with a temperature of 20-24°C and a humidity of 50-60%. The mice were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd.

[0131] (2) Animal grouping and intervention methods:

[0132] After a 7-day adaptation period, all mice were randomly divided into 12 groups: blank control group NC, model group MC, and yogurt groups prepared in Examples 1-2 and Comparative Examples 1-8. On the first day of the experiment, the blank control group and the model group were gavaged with 200 μL of normal saline, and the other yogurt groups were gavaged with 200 μL of yogurt. During the experiment, the mice were gavaged once a day. The modeling method was as follows: on the 15th to 17th day of the experiment, except for the blank control group, the mice in other groups were gavaged with 10 mg / kg.bw loperamide, and then gavaged with normal saline or yogurt 4 hours later. The specific situation is shown in Table 4.

[0133] Table 4

[0134]

[0135] (3) Safety evaluation in mice

[0136] During the animal experiment, body weight and food intake were measured twice a week to observe the health status of the mice. The results showed that before modeling, the body weight of each group of mice showed an upward trend, indicating that the intervention sample had no side effects on the weight gain of mice. There was no significant difference in the changes in body weight of each group of mice, and each group of mice gained more than 5%, indicating that the mice were healthy and growing well. The food utilization rate of each group of mice was similar to that of the control, and the food utilization rate was higher than 3%, indicating that each group of mice had good food utilization.

[0137] (4) Effect evaluation:

[0138] (4.1) Time of first black stool:

[0139] On the 18th day of the experiment, after fasting for 16 hours, the control group was gavaged with normal saline, and the other groups were gavaged with loperamide. One hour later, 0.2 mL of Chinese ink was gavaged per mouse. From the beginning of gavage with Chinese ink, the time of the first black stool of each mouse was recorded (min), and the time of the first black stool of the last mouse in the model group was taken as the end time.

[0140] The statistical results are shown in Table 5. Compared with the blank control group, the time for the mice in the model group to pass the first black stool was significantly prolonged. After the intervention of yogurt in each group, the time for the mice in each group to pass the first black stool was shortened to varying degrees, and the effects of Example 1 group and Example 2 group were significantly superior, indicating that the probiotics involved in the present invention have the effect of promoting intestinal peristalsis and moisturizing the intestine and relieving constipation.

[0141] (4.2) Small intestinal propulsion rate:

[0142] On the 19th day of the experiment, the control group was gavaged with normal saline, and the mice in the other groups were gavaged with loperamide. One hour later, all mice were gavaged with ink (0.2 mL / mouse). The mice were killed 25 minutes later, and the intestinal tube from the pylorus at the upper end to the ileum and cecum at the lower end was cut. The small intestine was gently pulled into a straight line, and the length of the intestinal tube was measured as the "total length of the small intestine", and the length from the pylorus to the front of the ink was the "ink advancement length", and the small intestine advancement rate (%) was calculated as ink advancement length / total length of the small intestine × 100%.

[0143] The statistical results are shown in Table 5. Compared with the blank control group, the small intestinal propulsion rate of the model group was significantly reduced. After intervention with yogurt in each group, the small intestinal propulsion rate of each group of mice recovered to varying degrees, among which the recovery effects of Example 1 and Example 2 groups were significantly superior, indicating that the probiotics involved in the present invention have the effect of promoting intestinal peristalsis and moisturizing the intestine and relieving constipation.

[0144] Table 5

[0145]

[0146] (4.3) Gastrointestinal regulatory peptide analysis:

[0147] After the experiment, the mice were dissected, blood was collected to separate serum, and the contents of four gastrointestinal regulatory peptides (Gas, SP, VIP, ET-1) in the mouse serum were determined by ELISA kit. The statistical results are shown in Table 6. Gas and SP are excitatory peptide neurotransmitters, while ET-1 and VIP are inhibitory peptide neurotransmitters. After intervention in each group, Gas and SP were improved compared with the model group, while ET-1 and VIP were significantly decreased, and the effects of Example 1 and Example 2 groups were the best, indicating that the yogurt prepared from the probiotics involved in the present invention can promote intestinal peristalsis.

[0148] Table 6

[0149]

[0150] (4.4) Analysis of inflammatory factors:

[0151] ELISA kits were used to determine the levels of inflammatory factors (IL-6, IL-10, TNF-α) in mouse serum. The statistical results are shown in Table 7. After intervention in each group, the anti-inflammatory factor IL-10 was increased compared with the model group, while the pro-inflammatory factors IL-6 and TNF-α were decreased, and the effects of Example 1 and Example 2 groups were the best.

[0152] Table 7

[0153]

[0154] (4.5) Metagenomic analysis of intestinal flora:

[0155] The cecum of mice in the blank control group, model group, Example 1 group, and Comparative Example 8 group was cut, and the intestinal flora metagenome was analyzed by 16S rDNA.

[0156] Firmicutes and Bacteroidetes account for the majority of intestinal flora. A detailed analysis was conducted on these two flora and the ratio of Firmicutes to Bacteroidetes (F / B). F / B is related to maintaining homeostasis. Figures 1 - 3 As shown, compared with the blank control group, the number of Firmicutes in the model group decreased, and the number of Bacteroidetes increased, indicating that as the mice are constipated, the beneficial bacteria in the cecum are less and the number of some pathogens increases; compared with the model group, the number of Firmicutes in the intervention group increased, and the number of Bacteroidetes significantly decreased, and the F / B was higher than that of the model group, indicating that the intake of the probiotic yogurt of the present invention has a promoting effect on the balance of intestinal flora.

[0157] Lachnospira can hydrolyze starch and other sugars to produce butyrate and other short-chain fatty acids; Alistipes helps the human body digest, absorb and regulate nutrients; Acinetobacter is a Gram-negative bacterium that causes infection when the body's resistance is reduced. It can colonize human skin, wounds, respiratory tract and gastrointestinal tract, and can also exist in oral biofilms. It is easy to cause pneumonia after being inhaled into the lower respiratory tract. The levels of these three bacterial communities were statistically analyzed, and the results are as follows: Figures 4 - 6As shown, compared with the model group, the number of Lachnospira and Alistipes in Example 1 group and Comparative Example 8 group increased, and the number of Acinetobacter decreased, and the effect of Example 1 group was significantly better, indicating that the intake of the probiotic yogurt of the present invention can reduce the number of harmful bacteria in the intestine and increase the number of beneficial bacteria, and it also shows that the balance of intestinal flora can be improved at the genus level.

[0158] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0159] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0160] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A composite probiotic agent, It is characterized in that The composite probiotic comprises a composite bifidobacterium agent and a basic agent; the strain in the composite bifidobacterium agent is a strain of Bifidobacterium animalis subsp. lactis with a preservation number of CGMCC No. 24029. Bifidobacterium animalis subsp. lactis BLa36 strain, Bifidobacterium longum with a deposit number of CGMCC No.10452 Bifidobacterium longum BL21 strain, Bifidobacterium breve with a deposit number of CGMCC No. 12915 Bifidobacterium breve BBr60 strain, Bifidobacterium adolescentis with a deposit number of CGMCC No. 19884 Bifidobacterium adolescentis BAC30 strain, Bifidobacterium infantis with a deposit number of CGMCC No. 15134 Bifidobacterium infantis BI45 strain composition; The strain in the basic bacterial agent is Streptococcus thermophilus with a deposit number of CGMCC No. 15752. Streptococcus thermophilus ST81 strain and Lactobacillus delbrueckii subsp. bulgaricus with a deposit number of CGMCC No. 15751 Lactobacillus delbrueckii subsp. bulgaricus LB42 strain composition.

2. The composite probiotic according to claim 1, It is characterized in that The ratio of the number of viable bacteria of the BLa36 strain, BL21 strain, BBr60 strain, BAC30 strain and BI45 strain is (1-10):(1-10):(1-10):(1-5):(1-5).

3. The composite probiotic according to claim 1, It is characterized in that The total number of viable bacteria in the composite bifidobacterium agent is not less than 1×10 11 CFU / mL or 1×10 11 CFU / g.

4. The composite probiotic according to claim 1, It is characterized in that The dosage form of the composite bifidobacterium preparation includes solution, lyophilized powder, capsule, tablet or granule.

5. The composite probiotic according to claim 1, It is characterized in that The ratio of the viable count of the ST81 strain to the LB42 strain is 30:(0.001-10); The total number of viable bacteria in the basic bacterial agent is not less than 1×10 11 CFU / mL or 1×10 11 CFU / g; The mass ratio of the composite bifidobacterium bacterial agent to the basic bacterial agent is (10-300):(10-40); The dosage form of the composite probiotic includes solution, lyophilized powder, capsule, tablet or granule.

6. Use of the composite probiotic according to any one of claims 1 to 5 in yogurt fermentation.

7. The use according to claim 6, It is characterized in that The method for fermenting yogurt comprises: (1) Mixing raw milk and compound prebiotics, sterilizing and cooling to prepare a fermentation base; (2) Inoculating the composite probiotic into the fermentation base for fermentation.

8. The use according to claim 7, It is characterized in that The composite prebiotics include any one of fructooligosaccharides, galacto-oligosaccharides, xylooligosaccharides, isomaltooligosaccharides, soybean oligosaccharides, inulin, polydextrose, α-lactalbumin or lactoferrin, or a combination of at least two of them.

9. The use according to claim 7, It is characterized in that The compound prebiotics account for 0.01-1% of the fermentation base.

10. The use according to claim 7, It is characterized in that The inoculation amount of the composite probiotic is 20-300 g / T.

11. The use according to claim 7, It is characterized in that The fermentation temperature is 40-43°C, the fermentation time is 5-10 hours, and the fermentation end point is when the acidity reaches 70-80°T or pH=4.3-4.

5.

12. Use of the composite probiotic according to any one of claims 1 to 5 in the preparation of a product that promotes intestinal motility.

Citation Information

Cited By

  • Method for accelerating coagulation type yogurt curdling and enhancing water-holding capacity and hardness, black rice coagulation type yogurt, black rice leavening and application of black rice curdling type yogurt and black rice leavening

    CN119302359A

  • Preparation method of puffed black rice powder fermented yogurt curds capable of enhancing water-holding capacity and improving solidification viscoelasticity

    CN122074558A